Skip to main
SMTI

SMTI Stock Forecast & Price Target

SMTI Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sanara MedTech Inc. has demonstrated significant year-over-year growth in its surgical and chronic wound care product lines, particularly with surgical soft tissue repair products seeing a remarkable 24% increase, reaching $23.4 million. The company anticipates continued revenue growth driven by its strategic expansion of distribution partnerships and healthcare facility penetration, with projected topline growth of 13-17% expected in 2026. Additionally, the continuation of profitable operations from the third quarter of 2025 further supports a positive financial outlook, bolstered by anticipated benefits from contracts such as the Vizient agreement.

Bears say

Sanara MedTech reported net revenue of $26.3 million, demonstrating a year-over-year growth of 21.5%, yet this figure fell short of projections by $0.4 million. The company faces several risks, including lower-than-anticipated growth in revenue from its products and services, challenges in acquiring new customers, and the potential inability to launch new offerings, all of which could negatively impact future performance. Additionally, the reduced enterprise value to revenue multiple from 4.3x to 3.0x indicates market concerns, particularly following the departure from telehealth services.

SMTI has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sanara MedTech Inc. (SMTI) Forecast

Analysts have given SMTI a Buy based on their latest research and market trends.

According to 2 analysts, SMTI has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sanara MedTech Inc. (SMTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.